Skip to main content
SpringerLink
Log in

Bone health in multiple sclerosis

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

People who are disabled with multiple sclerosis (MS) may be at increased risk of osteoporosis. This review discusses issues relevant to bone health in MS and makes practical recommendations regarding prevention and screening for osteoporosis and fracture risk in MS. A search of the literature up until 5 April 2011 was performed using key search terms, and articles pertinent to bone health in MS were analysed. Bone mineral density (BMD) is reduced at the lumbar spine, hip and total body in MS, with the degree of reduction being greatest at the hip. A strong relationship exists between the disability level, measured by the Expanded Disability Status Score, and BMD at the lumbar spine and femoral neck, particularly the latter. The rate of loss of BMD also correlates with the level of disability. Pulsed corticosteroids for acute episodes of MS, even with a high cumulative steroid dose, do not significantly affect BMD, but an effect on fracture risk is yet to be elucidated. There appears to be no correlation between vitamin D levels and BMD, and the relationship between disability and vitamin D levels remains unclear. Falls and fractures are more common than in healthy controls, and the risk rises with increasing levels of disability. The principal factor resulting in low BMD and increased fracture risk in MS is immobility. Antiresorptive therapy with bisphosphonates and optimising vitamin D levels are likely to be effective interventions although there are no randomised studies of this therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517

    Article  PubMed  CAS  Google Scholar 

  2. National Institute for Clinical Excellence (2003) Multiple sclerosis: management of multiple sclerosis in primary and secondary care. National Institute for Clinical Excellence, London

  3. Steffensen LH, Jorgensen L, Straume B, Mellgren SI, Kampman MT (2011) Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol (in press)

  4. Francis J, Gaywood I (2009) A cross-sectional study of bone health in multiple sclerosis

  5. Havrdova E, Tyblova M, Stepan JJ, Zikan V, Horakova D, Ticha V, Novakova I (2002) Osteoporosis in multiple sclerosis patients treated with corticosteroids. Mult Scler 8:S79

    Google Scholar 

  6. Hotermans C, Dive D, Rinkin, Leroy M, Malaise M, Moonen G, Franchimont N (2006) Hip bone mineral density is correlated with EDSS in patients with multiple sclerosis. J Neurol 257(3):410–418

  7. Gallagher E, Epstein S, Weppner D, Wrest K, Weinstock-Guttman B, Brownscheidle C, Patrick K, Jacobs L (2002) Bone loss in women with multiple sclerosis. International Journal of MS Care 4:3

    Google Scholar 

  8. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J et al (1998) Fracture history and bone loss in patients with MS. Neurology 51:1161–1165

    PubMed  CAS  Google Scholar 

  9. Tuzun S, Altintas A, Karacan I, Tangurek S, Saip S, Siva A (2003) Bone status in multiple sclerosis: beyond corticosteroid. Mult Scler 9:600–604

    Article  PubMed  Google Scholar 

  10. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y (2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23:309–313

    Article  PubMed  Google Scholar 

  11. Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R (1997) Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61:129–133

    Article  PubMed  CAS  Google Scholar 

  12. Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 12:550–556

    Article  PubMed  CAS  Google Scholar 

  13. Terzi T, Terzi M, Tander B, Canturk F, Onar M (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 17:1260–1264

    Article  PubMed  Google Scholar 

  14. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A (2004) Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89:4923–4928

    Article  PubMed  CAS  Google Scholar 

  15. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692

    PubMed  CAS  Google Scholar 

  16. Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M (2004) Risk of bone loss in men with multiple sclerosis. Mult Scler 10:170–175

    Article  PubMed  Google Scholar 

  17. Mojtahedi MC, Snook EM, Motl RW, Evans EM (2008) Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 45:851–861

    Article  PubMed  Google Scholar 

  18. Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM (2009) Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 178:43–45

    Article  PubMed  CAS  Google Scholar 

  19. Schwid SR, Goodman AD, Edward PJ, McDermott MP, Mattson DH (1996) Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53:753–757

    PubMed  CAS  Google Scholar 

  20. El-Ghoneimy AT, Gad AH, Samir H, Shalaby NM (2009) Contribution of vitamin D to the pathogenesis of multiple sclerosis and its effect on bone. Egyptian Journal of Neurology, Psychiatry and Neurosurgery 46:209–222

    Google Scholar 

  21. Proctor DN, Melton LJ, Khosla S, Crowson CS, O’Connor MK, Riggs BL (2000) Relative influence of physical activity, muscle mass and strength on bone density. Osteoporos Int 11:944–952

    Article  PubMed  CAS  Google Scholar 

  22. Lambert CP, Lee AR, Evans WJ (2002) Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 83:1559–1561

    Article  PubMed  Google Scholar 

  23. Stepan JJ, Havrdova E, Tyblova M, Horakova D, Ticha V, Novakova I, Zikan V (2004) Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clin Chim Acta 348:147–154

    Article  PubMed  CAS  Google Scholar 

  24. Sabo D, Blaich S, Wenz W, Hohmann M, Loew M, Gerner HJ (2001) Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch Orthop Trauma Surg 121:75–78

    Article  PubMed  CAS  Google Scholar 

  25. Slade JM, Bickel CS, Modlesky CM, Majumdar S, Dudley GA (2005) Trabecular bone is more deteriorated in spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int 16:263–272

    Article  PubMed  Google Scholar 

  26. Jiang SD, Dai LY, Jiang LS (2006) Osteoporosis after spinal cord injury. Osteoporos Int 17:180–192

    Article  PubMed  Google Scholar 

  27. Pang MY, Eng JJ, McKay HA, Dawson AS (2005) Reduced hip bone mineral density is related to physical fitness and leg lean mass in ambulatory individuals with chronic stroke. Osteoporos Int 16:1769–1779

    Article  PubMed  Google Scholar 

  28. Jorgensen L, Jacobsen BK, Wilsgaard T, Magnus JH (2000) Walking after stroke: does it matter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int 11:381–387

    Article  PubMed  CAS  Google Scholar 

  29. Del PA, Pappone N, Mandes MG, Mantova D, Scarpa R, Oriente P (1996) Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int 6:50–54

    Article  Google Scholar 

  30. Stenager E, Jensen K (1991) Fractures in multiple sclerosis. Acta Neurol Belg 91:296–302

    PubMed  CAS  Google Scholar 

  31. Peterson EW, Cho CC, von KL, Finlayson ML (2008) Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 89:1031–1037

    Article  PubMed  Google Scholar 

  32. Troiano RA, Jotkowitz A, Cook SD, Bansil S, Zito G (1992) Rate and types of fractures in corticosteroid-treated multiple sclerosis patients. Neurology 42:1389–1391

    PubMed  CAS  Google Scholar 

  33. Williams P, Frank A, Crawford CM et al (1984) Unrecongised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J 189:501

    Article  Google Scholar 

  34. Aggarwal A, Parvizi J, Ganz R (2004) Bilateral spontaneous periacetabular fracture: an unusual complication of multiple sclerosis. J Orthop Trauma 18:182–185

    Article  PubMed  Google Scholar 

  35. Cocksedge S, Freestone S, Martin JF (1984) Unrecognised femoral fractures in patients with paraplegia due to multiple sclerosis. Br Med J Clin Res Ed 289:309

    Article  PubMed  CAS  Google Scholar 

  36. Logan WC Jr, Sloane R, Lyles KW, Goldstein B, Hoenig HM (2008) Incidence of fractures in a cohort of veterans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil 89:237–243

    Article  PubMed  Google Scholar 

  37. Sibley WA, Bamford CR, Clark K, Smith MS, Laguna JF (1991) A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 54:584–589

    Article  PubMed  CAS  Google Scholar 

  38. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62:174–180

    Article  PubMed  CAS  Google Scholar 

  39. Marrie RA, Cutter G, Tyry T, Vollmer T (2009) A cross-sectional study of bone health in multiple sclerosis. Neurology 73:1394–1398

    Article  PubMed  Google Scholar 

  40. Bazelier M, van Staa T, Leufkens H, Vestergaard P, Cooper C, Uitdehaag B, Lalmohamed A, de Vries F (2010) Risk of fracture in patients with multiple sclerosis: a population-based cohort study. Osteoporos Int 21:S450–S451

    Google Scholar 

  41. Finlayson ML, Peterson EW, Cho CC (2006) Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 87:1274–1279

    Article  PubMed  Google Scholar 

  42. Cattaneo D, De NC, Fascia T, Macalli M, Pisoni I, Cardini R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867

    Article  PubMed  Google Scholar 

  43. Kirby RL, Ackroyd-Stolarz SA, Brown MG, Kirkland SA, MacLeod DA (1994) Wheelchair-related accidents caused by tips and falls among noninstitutionalised users of manually propelled wheelchairs in Nova Scotia. Am J Phys Med Rehabil 73:319–330

    Article  PubMed  CAS  Google Scholar 

  44. Nilsagard Y, Lundholm C, Denison E, Gunnarsson LG (2009) Predicting accidental falls in people with multiple sclerosis—a longitudinal study. Clin Rehabil 23:259–269

    Article  PubMed  CAS  Google Scholar 

  45. Cattaneo D, DeNuzzo C, Fascia T, Macalli M, Pisoni I, Cardoni R (2002) Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 83:864–867

    Article  PubMed  Google Scholar 

  46. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassey EJ (1988) Falls by elderly people at home: prevalence and associated factors. Age Ageing 17:365–372

    Article  PubMed  CAS  Google Scholar 

  47. O’Loughlin JL, Robitaille Y, Boivin JF, Suissa S (1993) Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol 137:342–354

    PubMed  Google Scholar 

  48. Tinetti ME, Speechley M, Ginter SF (1988) Risk factors for falls among elderly persons living in the community. N Engl J Med 319:1701–1707

    Article  PubMed  CAS  Google Scholar 

  49. Cameron MH, Poel AJ, Haselkorn JK, Linke A, Bourdette D (2011) Falls requiring medical attention among veterans with multiple sclerosis: a cohort study. J Rehabil Res Dev 48:13–20

    Article  PubMed  Google Scholar 

  50. Ardissone P, Rota E, Durelli L, Limone P, Isaia GC (2002) Effects of high doses of corticosteroids on bone metabolism. J Endocrinol Investig 25:129–133

    CAS  Google Scholar 

  51. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R (1994) High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9:1097–1105

    Article  PubMed  CAS  Google Scholar 

  52. Bergh FT, Kumpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismuller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP (2006) Monthly intravenous methylprednisolone in relapsing–remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 6:19

    Article  Google Scholar 

  53. Steffensen LH, Mellgren SI, Kampman MT (2010) Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 257:410–418

    Article  PubMed  Google Scholar 

  54. Achiron A, Edelstein S, Ziev-Ner Y, Givon U, Rotstein Z, Barak Y (2004) Bone strength in multiple sclerosis: Cortical midtibial speed-of-sound assessment. Mult Scler 10:488–493

    Article  PubMed  Google Scholar 

  55. Frediani B, Falsetti P, Bisogno S, Baldi F, Acciai C, Filippou G, Bacarelli MR, Filipponi P, Galeazzi M, Marcolongo R (2004) Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J Rheumatol 31:1083–1087

    PubMed  CAS  Google Scholar 

  56. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229

    Article  PubMed  Google Scholar 

  57. Van Staa TP, Geusens P, Pols HA, De LC, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198

    Article  PubMed  Google Scholar 

  58. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389

    Article  Google Scholar 

  59. Vestergaard P, Rejnmark L, Mosekilde L (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int 82:249–257

    Article  PubMed  CAS  Google Scholar 

  60. Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  61. de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214

    Article  PubMed  Google Scholar 

  62. Institute of Medicine of the National Academies (2010) Dietary reference intakes for calcium and vitamin D. In: Ross CA, Taylor AL, Yaktine AL, Del Valle HB (eds) National Academies Press, Washington, DC, p 1132

  63. Simmons RD, Ponsonby A-L, van der Mei IA, Sheridan P (2004) What affects your MS? Responses to an anonymous, internet-based epidemiological survey. Mult Scler 10:202–211

    Article  PubMed  Google Scholar 

  64. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:152–157

    Article  PubMed  CAS  Google Scholar 

  65. Hiremath GS, Cettomai D, Baynes M, Ratchford JN, Newsome S, Harrison D, Kerr D, Greenberg BM, Calabresi PA (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 15:735–740

    Article  PubMed  CAS  Google Scholar 

  66. van der Mei IA, Ponsonby A-L, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590

    Article  PubMed  Google Scholar 

  67. Barnes MS, Bonham MP, Robson PJ, Strain JJ, Lowe-Strong AS, Eaton-Evans J, Ginty F, Wallace JM (2007) Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 13:670–672

    Article  PubMed  CAS  Google Scholar 

  68. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11:266–271

    Article  PubMed  CAS  Google Scholar 

  69. Kragt J, van AB, Killestein J, Dijkstra C, Uitdehaag B, Polman C, Lips P (2009) Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15:9–15

    Article  PubMed  CAS  Google Scholar 

  70. Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132:1146–1160

    Article  PubMed  Google Scholar 

  71. Varoglu AO, Varoglu E, Bayraktar R, Aygul R, Ulvi H, Yildirim K (2010) The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23:25–29

    PubMed  Google Scholar 

  72. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409

    Article  PubMed  CAS  Google Scholar 

  73. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L (2004) Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155:155–160

    Article  PubMed  CAS  Google Scholar 

  74. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas NJ, Rio J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158:231–239

    Article  PubMed  CAS  Google Scholar 

  75. Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276:41–44

    Article  PubMed  CAS  Google Scholar 

  76. Shabas D, Weinreb H (2000) Preventive healthcare in women with multiple sclerosis. J Womens Health Gend-Based Med 9:389–396

    Article  PubMed  CAS  Google Scholar 

  77. Sharts-Hopko NC, Sullivan MP (2002) Beliefs, perceptions, and practices related to osteoporosis risk reduction among women with multiple sclerosis. Rehabil Nurs 27:232–237

    PubMed  Google Scholar 

  78. Sharts-Hopko NC, Smelter S (2004) Perceptions of women with multiple sclerosis about osteoporosis follow-up. J Neurosci Nurs 36:189–194

    Article  PubMed  Google Scholar 

  79. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    PubMed  CAS  Google Scholar 

  80. Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430–1438

    Article  PubMed  CAS  Google Scholar 

  81. Trojano M, Paolicelli D, Bellacosa A, Cataldo S (2003) The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 24(Suppl 5):S268–S270

    Article  PubMed  Google Scholar 

  82. Leray E, Yaouanq J, Le PE, Coustans M, Laplaud D, Oger J, Edan G (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:1900–1913

    Article  PubMed  Google Scholar 

  83. Cakt BD, Nacir B, Genc H, Saracoglu M, Karagoz A, Erdem HR, Ergun U (2010) Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 89:446–457

    Article  PubMed  Google Scholar 

  84. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T (2009) Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 73:1478–1484

    Article  PubMed  CAS  Google Scholar 

  85. Stroud NM, Minahan CL (2009) The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis. Health Qual Life Outcomes 7:68

    Article  PubMed  Google Scholar 

  86. Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention 1. Age Ageing 35(Suppl 2):ii37–ii41

    Article  PubMed  Google Scholar 

  87. Snook EM, Motl RW (2009) Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair 23:108–116

    PubMed  Google Scholar 

  88. Bischoff-Ferrari HA (2007) How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 18:401–407

    Article  PubMed  CAS  Google Scholar 

  89. Musso C, Liakopoulos V, Pangre N, DiTrolio J, Jauregui R, De MR, Stefanidis I, Imperiali N, Algranati L (2009) Renal physiology in elderly persons with severe immobility syndrome. Int Urol Nephrol 41:437–441

    Article  PubMed  Google Scholar 

  90. Poole KE, Reeve J, Warburton EA (2002) Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke 33:1432–1436

    Article  PubMed  Google Scholar 

  91. Sato Y, Iwamoto J, Kanoko T, Satoh K (2006) Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord 21:924–929

    Article  PubMed  Google Scholar 

  92. Poorjavad M, Derakhshandeh F, Etemadifar M, Soleymani B, Minagar A, Maghzi AH (2010) Oropharyngeal dysphagia in multiple sclerosis. Mult Scler 16:362–365

    Article  PubMed  Google Scholar 

  93. Herndon RM, Mohandas N (2000) Osteoporosis in multiple sclerosis: a frequent, serious, and under-recognized problem. In J MS Care 2:5–12

    Google Scholar 

  94. Edlich RF, Mason SS, Reddig JS, Gubler K, Long WB III (2010) A case report: femoral fracture in a multiple sclerosis patient with vitamin D deficiency—a preventable injury. J Environ Pathol Toxicol Oncol 29:3–5

    PubMed  Google Scholar 

Download references

Acknowledgments

We wish to acknowledge Drs. James Francis and Ian Gaywood for their personal communications and provision of their unpublished data. We would also like to thank Apostolos Fakis for the statistical advice.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Level 2, Department of Rehabilitation Medicine, Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3NE, UK

    J. C. Gibson

  2. Department of Rheumatology, Royal Derby Hospital, Derby, UK

    G. D. Summers

Authors
  1. J. C. Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. D. Summers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. C. Gibson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibson, J.C., Summers, G.D. Bone health in multiple sclerosis. Osteoporos Int 22, 2935–2949 (2011). https://doi.org/10.1007/s00198-011-1644-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1644-8

Keywords

Search

Navigation